90% of Americans Are at Risk for a Syndrome Most Have Never Heard Of

What CKM Syndrome Actually Is

The American Heart Association formally defined cardiovascular-kidney-metabolic syndrome in October 2023. The concept is straightforward: heart disease, kidney disease, diabetes, and obesity don't just coexist in the same patients. They actively make each other worse.

When one of those systems breaks down, it accelerates damage in the others. The AHA's position, explained by Chief Medical Officer for Prevention Dr. Eduardo Sanchez, is that treating these conditions separately — as medicine has historically done — misses the compounding risk entirely.

"The heart, kidney and metabolic systems are connected and, as such, should be treated in a coordinated way," Sanchez said in the AHA's October 2023 statement.

The Scale of the Problem

A study published in JAMA found that nearly 90% of U.S. adults have at least one CKM risk factor. Those include high blood pressure, abnormal cholesterol, elevated blood glucose, excess weight, and reduced kidney function.

Separately, JAMA published data from the National Health and Nutrition Examination Survey covering 11,570 adults between 2013 and 2023. The weighted prevalence of metabolic syndrome — a narrower cluster requiring at least three of five specific clinical markers — sat at 38.7% of U.S. adults as of the 2021-23 survey cycle, up from 35.4% a decade earlier. The increase was not statistically significant overall, but subgroup trends were.

Rates rose significantly among older adults and Black Americans. Hypertriglyceridemia, one component of metabolic syndrome, dropped from 23.7% in 2013-14 to 20% in 2017-20, then climbed back to 25.1% in 2021-23, a non-linear pattern the researchers attributed in part to COVID-19 disruptions in lifestyle and healthcare access.

Most People Have No Idea

The Harris Poll surveyed roughly 4,000 U.S. adults in August 2025 on behalf of the AHA. The finding: approximately 9 in 10 Americans have never heard of CKM syndrome.

Once the term was explained, nearly three-quarters of respondents said it sounded important and they wanted to learn more. The risk is widespread. The ignorance is nearly as widespread. Awareness collapses the distance between the two almost immediately.

Cardiologist Dr. Nidhi Kumar, speaking to CBS New York in 2023, noted that 33% of Americans have three or more CKM risk factors simultaneously, and said: "When we think of danger in medicine, sometimes people think of the words 'cancer' or 'COVID,' but chronic diseases, like those that make up CKM, are the leading cause of death and disability in the United States."

The Staging System Matters

The Cleveland Clinic outlines CKM syndrome on a five-stage scale. Stage 0 is no risk factors. Stage 1 is excess body fat. Stage 2 introduces conditions like Type 2 diabetes, high blood pressure, or kidney disease. Stage 3 means silent or high-risk heart disease. Stage 4 means active heart disease with compounding metabolic and kidney conditions.

The staging framework is clinically useful because it allows earlier intervention. Most people sitting at Stage 1 or 2 today are reversible with diet and physical activity changes, according to the AHA. That window closes as the conditions compound.

The Strongest Counter-Argument

Skeptics — including some clinicians — argue that bundling these conditions under a new umbrella label risks pathologizing normal variation, inflating the apparent prevalence of disease, and creating pharmaceutical markets around conditions that should be addressed through basic lifestyle changes. There's a reasonable concern that a broad new syndrome designation generates treatment protocols before the research base for coordinated care is fully established.

That concern deserves a direct answer: the AHA's own framing acknowledges that for most people, CKM syndrome is reversible with eating and activity changes. The clinical case for the new designation isn't primarily about new drugs. It's about getting cardiologists, nephrologists, and endocrinologists to talk to each other and treat the same patient as a system rather than as separate organ problems. Whether the medical establishment can actually execute that coordination remains unclear.

What's Coming

The AHA announced plans to issue its first-ever clinical guidelines specifically on CKM syndrome in early 2026. Those guidelines are intended to be the first formal standard of care for treating these conditions as an interconnected system rather than individually.

The JAMA metabolic syndrome data flagged one unresolved problem that the new guidelines will need to address directly: the widening disparity in older and Black populations. If the coordinated-care model the AHA is building doesn't reach those groups at higher rates than current fragmented care does, the guidelines will succeed on paper and fail in practice.